Prevention and Control of Seasonal Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2017-18 Influenza Season

This report updates the 2016-17 recommendations of the Advisory Committee on Immunization Practices (ACID) regarding the use of seasonal influenza vaccines (MMWR Recomm Rep 2016;65[No. RR-5D]). Routine annual influenza vaccination is recommended for all persons aged months who do not have contraindications. A licensed, recommended and age-appropriate vaccine should be used. For the 2017-18 season, quadrivalent and trivalent influenza vaccines will be available. Inactivated influenza vaccines (IIVs) will be available in trivalent (IIV3) and quadrivalent (IIV4) formulations. Recombinant influenza vaccine (RIV will be available in trivalent (RIV3) and quadrivalent (RIV4) formulations. Live attenuated influenza vaccine (LAIV4) is not recommended for use during the 2017-18 season due to concerns about its effectiveness against (H1N1)pdm09 viruses during the 2013-14 and 2015-16 seasons. Recommendations for different vaccine types and specific populations are discussed. No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one licensed recommended product is available. Updates to the recommendations described in this report reflect discussions during public meetings of ACIP held on October 20, 2016; February 22, 2017; and June 21, 2017. New and updated information in this report includes the following: Vaccine viruses included in the 2017-18 US. trivalent influenza vaccines will be an A/Michigan/45/2015 (H1N1) pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus, and a B/Brisbane/60/2008-like virus (Victoria lineage). Quadrivalent influenza vaccines will contain these three viruses and an additional influenza B vaccine virus, a B/Phuket/3073/2013-like virus (Yamagata lineage). Information on recent licensures and labelling changes is discussed including licensure of Afluria Quadrivalent (IIV4; Seqirus, Parkville, Victoria, Australia); Flublok Quadrivalent (RIV4; Protein Sciences, Meriden, Connecticut); and expansion of the age indication for FluLaval Quadrivalent (IIV4; ID Biomedical Corporation of Quebec, Quebec City, Quebec, Canada), previously licensed for years, to months. Pregnant women may receive any licensed, recommended age-appropriate influenza vaccine. Afluria (IIV3; Seqirus, Parkville, Victoria, Australia) may be used forpersons aged years, consistent with Food and Drug Administration-approved labeling. FluMist Quadrivalent (LAIV4; MedImmune, Gaithersburg Maryland) should not be used during the 2017-18 season due to concerns about its activeness against influenza A(H1N1)pdm09 viruses in the United States during the 2013-14 and 2015-16 influenza seasons.